Van­da los­es Het­lioz patent court de­ci­sion, vows to ap­peal and ask for stay on Te­va, Apo­tex com­peti­tors

A fed­er­al judge in­val­i­dat­ed four of Van­da Phar­ma­ceu­ti­cals’ patents for sleep med Het­lioz on Tues­day, ef­fec­tive­ly open­ing the door to gener­ic tasimelteon com­pe­ti­tion from Te­va, Apo­tex and oth­ers. Van­da plans to ap­peal and is ask­ing for a stay against the com­pe­ti­tion in the mean­time.

“Van­da in­tends to ap­peal the de­ci­sion to the Unit­ed States Court of Ap­peals for the Fed­er­al Cir­cuit and to re­quest a stay of mar­ket en­try by Te­va and Apo­tex while the ap­peal is pend­ing,” the com­pa­ny said in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER